Rebecca Lehto on Complementary Modalities During Lung Cancer Treatment

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Merck has discontinued the KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in non-small cell lung cancer and cutaneous squamous cell carcinoma.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Breakthrough therapy designation has been granted by the FDA to GSK5764227 for potential use in some patients with extensive-stage SCLC.

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.